CTAD 2025: Key trends redefining therapeutic and diagnostic strategies in Alzheimer's disease - PubMed
4 hours ago
- #Alzheimer's disease
- #biomarkers
- #clinical trials
- New disease-modifying approaches in Alzheimer's disease (AD) include next-generation anti-amyloid-β and anti-tau antibodies, small-molecule aggregation inhibitors, and gene-based strategies.
- Blood-based biomarkers like p-tau217, p-tau181, glial fibrillary acidic protein, and neurofilament light are nearing clinical readiness.
- Digital biomarkers and wearable technologies are enabling remote, continuous assessment of cognitive and physiological functions.
- Clinical trial design is focusing on earlier disease stages and high-risk groups defined by genetics or biomarkers, using adaptive methodologies and real-world data.
- The AD care model is transitioning from a centralized, cognitive scale-driven approach to a decentralized, biomarker-guided precision paradigm.